Cargando…
LINC00324 in cancer: Regulatory and therapeutic implications
LINC00324 is a 2082 bp intergenic noncoding RNA. Aberrant expression of LINC00324 was associated with the risk of 11 tumors and was closely associated with clinicopathological features and prognostic levels of 7 tumors. LINC00324 can sponge multiple miRNAs to form complex ceRNA networks, and can als...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815511/ https://www.ncbi.nlm.nih.gov/pubmed/36620587 http://dx.doi.org/10.3389/fonc.2022.1039366 |
_version_ | 1784864334301626368 |
---|---|
author | Xia, Qing Shen, Jinze Wang, Qurui Ke, Yufei Yan, Qibin Li, Hanbing Zhang, Dayong Duan, Shiwei |
author_facet | Xia, Qing Shen, Jinze Wang, Qurui Ke, Yufei Yan, Qibin Li, Hanbing Zhang, Dayong Duan, Shiwei |
author_sort | Xia, Qing |
collection | PubMed |
description | LINC00324 is a 2082 bp intergenic noncoding RNA. Aberrant expression of LINC00324 was associated with the risk of 11 tumors and was closely associated with clinicopathological features and prognostic levels of 7 tumors. LINC00324 can sponge multiple miRNAs to form complex ceRNA networks, and can also recruit transcription factors and bind RNA-binding protein HuR, thereby regulating the expression of a number of downstream protein-coding genes. LINC00324 is involved in 4 signaling pathways, including the PI3K/AKT signaling pathway, cell cycle regulatory pathway, Notch signaling pathway, and Jak/STAT3 signaling pathway. High expression of LINC00324 was associated with larger tumors, a higher degree of metastasis, a higher TNM stage and clinical stage, and shorter OS. Currently, four downstream genes in the LINC00324 network have targeted drugs. In this review, we summarize the molecular mechanisms and clinical value of LINC00324 in tumors and discuss future directions and challenges for LINC00324 research. |
format | Online Article Text |
id | pubmed-9815511 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98155112023-01-06 LINC00324 in cancer: Regulatory and therapeutic implications Xia, Qing Shen, Jinze Wang, Qurui Ke, Yufei Yan, Qibin Li, Hanbing Zhang, Dayong Duan, Shiwei Front Oncol Oncology LINC00324 is a 2082 bp intergenic noncoding RNA. Aberrant expression of LINC00324 was associated with the risk of 11 tumors and was closely associated with clinicopathological features and prognostic levels of 7 tumors. LINC00324 can sponge multiple miRNAs to form complex ceRNA networks, and can also recruit transcription factors and bind RNA-binding protein HuR, thereby regulating the expression of a number of downstream protein-coding genes. LINC00324 is involved in 4 signaling pathways, including the PI3K/AKT signaling pathway, cell cycle regulatory pathway, Notch signaling pathway, and Jak/STAT3 signaling pathway. High expression of LINC00324 was associated with larger tumors, a higher degree of metastasis, a higher TNM stage and clinical stage, and shorter OS. Currently, four downstream genes in the LINC00324 network have targeted drugs. In this review, we summarize the molecular mechanisms and clinical value of LINC00324 in tumors and discuss future directions and challenges for LINC00324 research. Frontiers Media S.A. 2022-12-22 /pmc/articles/PMC9815511/ /pubmed/36620587 http://dx.doi.org/10.3389/fonc.2022.1039366 Text en Copyright © 2022 Xia, Shen, Wang, Ke, Yan, Li, Zhang and Duan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Xia, Qing Shen, Jinze Wang, Qurui Ke, Yufei Yan, Qibin Li, Hanbing Zhang, Dayong Duan, Shiwei LINC00324 in cancer: Regulatory and therapeutic implications |
title | LINC00324 in cancer: Regulatory and therapeutic implications |
title_full | LINC00324 in cancer: Regulatory and therapeutic implications |
title_fullStr | LINC00324 in cancer: Regulatory and therapeutic implications |
title_full_unstemmed | LINC00324 in cancer: Regulatory and therapeutic implications |
title_short | LINC00324 in cancer: Regulatory and therapeutic implications |
title_sort | linc00324 in cancer: regulatory and therapeutic implications |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9815511/ https://www.ncbi.nlm.nih.gov/pubmed/36620587 http://dx.doi.org/10.3389/fonc.2022.1039366 |
work_keys_str_mv | AT xiaqing linc00324incancerregulatoryandtherapeuticimplications AT shenjinze linc00324incancerregulatoryandtherapeuticimplications AT wangqurui linc00324incancerregulatoryandtherapeuticimplications AT keyufei linc00324incancerregulatoryandtherapeuticimplications AT yanqibin linc00324incancerregulatoryandtherapeuticimplications AT lihanbing linc00324incancerregulatoryandtherapeuticimplications AT zhangdayong linc00324incancerregulatoryandtherapeuticimplications AT duanshiwei linc00324incancerregulatoryandtherapeuticimplications |